A Phase 1, Open-Label, Sequential Cross-over, Bioavailability/Bioequivalence Study to Compare the Pharmacokinetics of Oral Cladribine With the Reference Listed Drug, Intravenous Cladribine
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
Hackensack Meridian Health
Medical College of Wisconsin
M.D. Anderson Cancer Center
Emory University
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
H. Lee Moffitt Cancer Center and Research Institute
M.D. Anderson Cancer Center
Institut Curie
OHSU Knight Cancer Institute
Roswell Park Cancer Institute
Weill Medical College of Cornell University
Fred Hutchinson Cancer Center
M.D. Anderson Cancer Center
Thomas Jefferson University
M.D. Anderson Cancer Center
University of Michigan Rogel Cancer Center
M.D. Anderson Cancer Center
University of Florida
Memorial Sloan Kettering Cancer Center
Fred Hutchinson Cancer Center
Gruppo Italiano Malattie EMatologiche dell'Adulto
Fred Hutchinson Cancer Center
M.D. Anderson Cancer Center
Mayo Clinic
M.D. Anderson Cancer Center
Loyola University
Mayo Clinic
Columbia University
OHSU Knight Cancer Institute
Weill Medical College of Cornell University
University of Utah
GWT-TUD GmbH
Rutgers, The State University of New Jersey
Duke University
Centre Hospitalier Universitaire de Saint Etienne
Goethe University
Charite University, Berlin, Germany
University of Michigan Rogel Cancer Center
Fred Hutchinson Cancer Center
Medical College of Wisconsin
University of Michigan Rogel Cancer Center
Gruppo Italiano Malattie EMatologiche dell'Adulto
Roswell Park Cancer Institute
Dana-Farber Cancer Institute
Baylor College of Medicine
University of Utah
Wake Forest University Health Sciences
Memorial Sloan Kettering Cancer Center